February 28, 2026European Heart Journal - Cardiovascular Pharmacotherapy0 citationsOpen Access
Beta-blockers after myocardial infarction: time to change the guidelines
View Full Paper
Key Result
Long-term beta-blocker therapy in patients with myocardial infarction and preserved ejection fraction is increasingly questioned in the context of contemporary care.
Key Points
- To assess the necessity of long-term beta-blocker therapy in myocardial infarction patients with preserved ejection fraction.
- Evaluated patients with myocardial infarction and preserved ejection fraction
- Analyzed contemporary care practices and their implications on beta-blocker therapy
- Long-term beta-blocker therapy benefits in modern clinical settings are questionable
- Evidence suggests potential reevaluation of existing treatment guidelines
Structured PICO
Does long-term beta-blocker therapy improve outcomes in patients with myocardial infarction and preserved ejection fraction receiving contemporary care?
P
Population
Patients with myocardial infarction (MI) and preserved ejection fraction (EF) receiving contemporary care
I
Intervention
Long-term beta-blocker therapy
The necessity of long-term beta-blocker therapy in post-MI patients with preserved ejection fraction is being questioned, suggesting a potential need for guideline updates.
Abstract
The role of long-term beta-blocker therapy in patients with myocardial infarction (MI) and preserved ejection fraction (EF) receiving contemporary care has increasingly been questioned.
Cite This Study
Tomas Jernberg (2026) studied this question. Long-term beta-blocker therapy in patients with myocardial infarction and preserved ejection fraction is increasingly questioned in the context of contemporary care.